We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Complete Blood Count Risk Score Predict Life Expectancy

By LabMedica International staff writers
Posted on 05 Dec 2013
A simple blood test may predict who is at the highest risk to develop heart problems and how long these people may have to live. More...


The complete blood count (CBC) risk score is an inexpensive tool that uses all of the information in the common blood test, which includes laboratory data that is frequently underused.

Scientists at the Intermountain Medical Center Heart Institute (Murray, UT, USA) collaborating with those at Brigham and Women's Hospital (Boston, MA, USA) used CBC laboratory testing information gathered as part of the Justification for the Use of Statins in Primary Prevention (JUPITER) Trial, a randomized clinical trial of a cholesterol-lowering drug.

The JUPITER study enrolled more than 17,000 individuals in 26 countries and followed them for up to five years. Participants in JUPITER had a clean slate free of cardiovascular disease normal low-density-lipoprotein cholesterol, but elevated C-reactive protein, a marker of inflammation associated with cardiovascular disease.

Individuals in the trial with a lower CBC risk score were very unlikely to die, while those with CBC risk scores in the middle of the range had more than 50% higher risk of death. People with the highest CBC risk scores were about twice as likely to die as those with low scores. The CBC risk score and its parent risk score, the Intermountain Risk Score, which is a combination of the CBC laboratory test and the basic metabolic profile blood test, were created to provide useful health information to allow physicians to easily compute the risk score while continuing to care for patients.

Benjamin Horne, PhD, director of cardiovascular and genetic epidemiology at the Intermountain Medical Center, said, “We now have a standardized way of assessing the risk of mortality for all individuals, not just ones with a history of heart diseases. One of the beauties of this score is it uses clinically familiar, standardized medical information already in electronic format. The financial cost is also almost zero because most patients already receive the CBC test. The clinical cost is also low, because of electronic medical records. Physicians receive this critical information about future risk, which adds to their knowledge about the patient, while it takes very little of their time or effort to obtain the information.” The study was presented at the American Heart Association Scientific Sessions, held November 16-20, 2013, in Dallas (TX, USA. 

Related Links:
Intermountain Medical Center Heart Institute
Brigham and Women's Hospital 


New
Gold Member
Aspiration System
VACUSAFE
Online QC Software
Acusera 24•7
New
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
New
Benchtop Thermomixer
Biometra TS1 ThermoShaker
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Roche’s CE-Marked Elecsys pTau217 blood test is a single‑assay blood test measures phosphorylated tau 217, an indicator of amyloid pathology and a hallmark of Alzheimer’s disease (image credit: Shutterstock)

Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection

Alzheimer’s disease is the most common cause of dementia, yet confirmatory testing remains invasive and hard to access. Diagnosis currently takes an average of 3.5 years, and about 75% of people with dementia... Read more

Molecular Diagnostics

view channel
Image: Clarifying tumor microenvironment features and cancer-cell programs linked to treatment response could provide earlier insight into triple-negative breast cancer therapy (image credit: Shutterstock)

Gene Panel Shows Promise for Predicting Chemotherapy Response in TNBC

Triple-negative breast cancer (TNBC) is an aggressive subtype commonly treated with chemotherapy, yet outcomes vary widely among patients. Understanding the tumor features that drive this variability remains... Read more

Microbiology

view channel
Image: The initiative combines epidemiological and microbiological data with whole-genome sequencing to characterize circulating hospital lineages and resistance determinants (image credit: Shutterstock)

Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals

Antimicrobial resistance (AMR) poses a growing threat to patient safety, with carbapenem-resistant Enterobacterales causing difficult-to-treat infections and leaving clinicians with limited therapeutic options.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.